Wang, Yongxia
Wang, Xinlu
Wang, Jianru
Li, Bin
Yu, Rui
Hu, Yucai
Li, Xingyuan
Peng, Guangcao
Zhang, Mengmeng
Zhu, Mingjun http://orcid.org/0000-0001-7646-6577
Funding for this research was provided by:
Ministry of Science and Technology (2018YFC1707402)
Ministry of Science and Technology (No. 2019YFC1710000)
Tianjin Zhongxin Pharmaceutical Group Co., Ltd.; Le Ren Tang Pharmaceutical Factory (No.2018YFC1707402)
Article History
Received: 19 December 2019
Accepted: 25 February 2020
First Online: 20 March 2020
Ethics approval and consent to participate
: This study will abide by the Declaration of Helsinki and has been subjected to vetting by the ethics committee of the First Affiliated Hospital of Henan University of TCM (ethics approval number: 2019HL-048-01). As of October 10, 2019, this study has been approved by seven centers of the ethics committee (ethics approval numbers: 2019HL-048-01, 2019–095-KY-04, K[2019]041, 2019–693–48-01, 2019–091-01, 2019164, and BF2019–085-01). We will not begin recruiting at other centers in the trial until local ethical approval has been obtained. All of the participants must signed informed consent documents before enrollment.All procedures performed in studies involving human participants will be in accordance with the ethical standards of the institutional or national research committee (or both) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: At the point of recruitment into the trial, all participants or their legally authorized representatives will be informed of the study protocol and consent will be provided for publication of the data. All of the participants will be fully anonymous.
: All of the authors declare that they have no competing interests. They will share their raw data and deposit it in the Electronic Data Capture repository (website: ExternalRef removed).